CARGO Therapeutics Engages Investors at Notable Conferences
CARGO Therapeutics, Inc. (NASDAQ: CRGX) is making significant strides as a clinical-stage biotechnology company, focusing on the development of potentially curative therapies targeting cancer. The company recently announced its attendance at several prestigious investor conferences that offer a platform for demonstrating their advances in cell therapy.
Upcoming Conference Participation
The first highlighted event is the Jefferies London Healthcare Conference, where Gina Chapman, the President and Chief Executive Officer of CARGO Therapeutics, is scheduled for a fireside chat on an important panel discussion. This engaging session is set for a Wednesday in November at 11:00 a.m. GMT, showcasing insights on innovative healthcare strategies.
Details on the Piper Sandler Conference
Following that, CARGO Therapeutics will participate in the distinguished Piper Sandler 36th Annual Healthcare Conference. Gina Chapman will again represent the company during a fireside chat on a Wednesday in December at 10:30 a.m. EST, marking another crucial opportunity to present their advances and engage with the investment community.
Accessing Live Webcasts
For those interested in gaining insights into these discussions, CARGO Therapeutics provides streaming access to the live webcasts from each conference. These can be found in the Investors section of their official website under the 'News & Events' category. Furthermore, replays of these webcasts will be accessible for approximately 90 days, allowing broader access to those unable to attend live.
About CARGO Therapeutics and Its Innovative Work
CARGO Therapeutics stands at the forefront of biotechnology, creating a unique position within the industry as a dedicated provider of innovative cancer treatment solutions. The company is currently pushing the boundaries of traditional therapies with programs that prioritize durability and safety in patient responses. Their lead candidate, firicabtagene autoleucel (firi-cel), is an autologous CD22 chimeric antigen receptor (CAR) T-cell therapy that aims to address relapsed or refractory large B-cell lymphoma.
Advancing Research and Development
CARGO's proprietary technologies facilitate the development of various products within its robust pipeline. The cutting-edge CRG-023 program, which utilizes a tri-specific CAR T-cell design with CD2 co-stimulation, aims to improve patient outcomes by promoting long-lasting responses in a wider array of B-cell malignancies. These strategies address critical challenges seen in existing therapies, providing hope for those facing limited options.
Experienced Leadership Driving Innovation
CARGO Therapeutics is led by a team with substantial experience in the fields of oncology and cell therapy, working diligently to advance their mission of making curative cell therapies available. Their commitment to innovation and comprehensive research continues to guide their progress in fostering breakthroughs that can significantly improve patient outcomes.
Contact Information for Inquiries
For further information about CARGO Therapeutics, interested parties can reach out directly to their communication channels:
Media Contact:
Kimberly Muscara
Email: kimberly@redhousecomms.com
Investor Contact:
Jessica Serra
Email: jserra@cargo-tx.com
Laurence Watts
Email: laurence@newstreetir.com
Frequently Asked Questions
What is CARGO Therapeutics?
CARGO Therapeutics is a clinical-stage biotechnology company that develops next-generation cell therapies aimed at treating cancer.
What conferences is CARGO participating in?
CARGO is set to participate in the Jefferies London Healthcare Conference and the Piper Sandler 36th Annual Healthcare Conference.
Who are the key speakers for these events?
Gina Chapman, the President and CEO of CARGO Therapeutics, will be the primary speaker for both conferences.
How can I access the conference webcasts?
Live webcasts can be accessed on the Investors section of CARGO's website, with replays available for approximately 90 days.
What innovative therapies is CARGO currently developing?
CARGO is developing therapies such as firicabtagene autoleucel, targeting large B-cell lymphoma and addressing the shortcomings of existing treatments.
